v3.26.1
Segment Information - Schedule of Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Segment Information [Line Items]    
Revenue $ 1,442 $ 2,170
Less:    
Cost of revenues 284 154
Research and development expenses 202,016 152,919
Share-based compensation 83,342 82,178
General and administrative expenses 165,527 134,019
Gain on litigation settlement (392) 0
Change in fair value of investments (36,637) 19,125
Change in fair value of liability instruments 0 2,329
Interest income (36,922) (48,322)
Other expense, net 2,130 11,208
Income tax (benefit) expense (3,958) 4,649
Net loss (290,606) (273,911)
Reportable Segment    
Segment Information [Line Items]    
Revenue 1,442 2,170
Less:    
Cost of revenues 284 154
Other research and development expenses 7,859 9,637
Other general and administrative expenses 34,706 32,830
Gain on litigation settlement (392) 0
Change in fair value of investments (36,637) 19,125
Change in fair value of liability instruments 0 2,329
Interest income (36,922) (48,322)
Other expense, net 2,130 11,208
Income tax (benefit) expense (3,958) 4,649
Net loss (290,606) (273,911)
Anti-FcRn franchise—endocrine diseases | Reportable Segment    
Less:    
Research and development expenses 42,885 19,329
Anti-FcRn franchise—neurological diseases | Reportable Segment    
Less:    
Research and development expenses 25,455 20,937
Anti-FcRn franchise—rheumatology diseases | Reportable Segment    
Less:    
Research and development expenses 22,340 8,209
Anti-FcRn franchise—dermatology diseases | Reportable Segment    
Less:    
Research and development expenses 7,542 5,145
Anti-FcRn franchise—other clinical and nonclinical | Reportable Segment    
Less:    
Research and development expenses 2,609 2,392
Brepocitinib | Reportable Segment    
Less:    
Research and development expenses 14,092 15,020
Mosliciguat | Reportable Segment    
Less:    
Research and development expenses 13,041 8,385
Other development and discovery programs | Reportable Segment    
Less:    
Research and development expenses 11,118 10,236
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense    
Less:    
Share-based compensation 74,621 71,079
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Reportable Segment    
Less:    
Share-based compensation 74,621 71,079
Personnel-related expenses 56,200 30,110
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense    
Less:    
Share-based compensation 8,721 11,099
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment    
Less:    
Share-based compensation 8,721 11,099
Personnel-related expenses $ 46,354 $ 42,530